Related Experiment Video
Updated: Aug 28, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer
Bahriye Aktas1, Tanja N Fehm2, Manfred Welslau3
1Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany.
Abstract:
For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors - trastuzumab deruxtecan, sacituzumab govitecan and capivasertib - is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.
Insights
New treatments like trastuzumab deruxtecan and capivasertib show survival benefits for advanced HER2-negative hormone receptor-positive breast cancer. This review details recent findings and their clinical implications.
Area of Science:
- Oncology
- Medical Research
Background:
- Advanced HER2-negative, hormone receptor-positive breast cancer treatment landscape is evolving.
- Several novel therapeutic agents have emerged recently, with ongoing drug development.
Purpose of the Study:
- To review and synthesize recent clinical trial results for advanced HER2-negative, hormone receptor-positive breast cancer.
- To contextualize these findings within current treatment strategies.
Main Methods:
- Literature review of studies published in specialist journals and presented at congresses.
- Focus on therapies including CDK4/6 inhibitors, trastuzumab deruxtecan, sacituzumab govitecan, and capivasertib.
Main Results:
- Trastuzumab deruxtecan demonstrated an overall survival benefit in HER2-low expressing breast cancer (Destiny-Breast-04 study).
- Capivasertib also showed an overall survival benefit (FAKTION study).
- Palbociclib's lack of overall survival benefit in first-line therapy prompts re-evaluation.
Conclusions:
- Recent advancements offer new therapeutic options for advanced HER2-negative, hormone receptor-positive breast cancer.
- Specific agents like trastuzumab deruxtecan and capivasertib show promise for improved survival outcomes.
- Further research is needed to clarify the optimal clinical positioning of these therapies.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Cancer Survival Analysis